What is the market's earnings forecast for Abbvie next quarter?

What is Abbvie's gross profit margin?

What were the key takeaways from Abbvie’s earnings call?

What is Abbvie's latest dividend and current dividend yield?

What factors drove the changes in Abbvie's revenue and profit?

What guidance did Abbvie's management provide for the next earnings period?

Did Abbvie beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Abbvie year over year?

- **Record Growth**: Q3 revenue $15.8B (+8.4% YoY), beating estimates by $300M.
- **Pipeline Power**: Skyrizi/Rinvoq at $17.3B+ in 2025, neuroscience up 19.6% to $2.8B.
- **Dividend Boost**: 5.5% increase to $1.73/share, supported by $13B+ free cash flow.
- **Strategic Expansion**: $10B+ U.S. manufacturing investment; new API plant and biologics expansion.
- **Resilience**: Outperformed in oncology (+$1.7B), neuroscience (+$2.8B), despite macro headwinds in aesthetics.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $15.8 billion (+8.4% YoY), driven by 46% growth in Skyrizi and 34% in Rinvoq.
- **Pipeline Momentum**: 90+ programs across immunology, oncology, neuroscience, and aesthetics; Phase III data for Rinvoq in vitiligo and alopecia areata expected soon.
- **Strategic Investments**: $10 billion+ in U.S. manufacturing; new API plant in North Chicago and biologics expansion in Worcester.
- **Dividend Increase**: 5.5% hike to $1.73/share, reflecting strong free cash flow ($13B+ YTD).

**【CFO Financial Commentary】**
- **Earnings**: Adjusted EPS of $1.86 (vs. $1.76 guidance), with $400M revenue beat.
- **Margins**: Gross margin 83.9%, R&D 14.3%, SG&A 21.6%; operating margin 30.9%.
- **2025 Guidance Update**: Full-year revenue $16.9B (+$400M), EPS $10.61-$10.65.
- **2026 Outlook**: Expects high single-digit growth, supported by Skyrizi/Rinvoq (~$17.3B) and neuroscience (~$10.7B).

**【Q&A Highlights】**
- **PBM Model**: CEO confident in AbbVie's ability to adapt; differentiated medicines (e.g., VYALEV, tavapadon) mitigate PBM risks.
- **Aesthetics Recovery**: BOTOX share ~60%, Juvederm ~45%; new campaigns and TrenibotE launch in 2026 may drive rebound.
- **Pipeline Catalysts**: Rinvoq vitiligo/vitiligo data (Q4 2025), tavapadon FDA submission (Q4 2025), Temab-A Phase III in CRC (2026).

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: $15.4B Q2 revenue (+6.5% operational) vs. guidance, +$800M FY25 raise to $60.5B
- **Ex-HUMIRA Growth**: Skyrizi/Rinvoq on track for $25B+ annual sales
- **Pipeline Wins**: Rinvoq GCA approval, EMRELIS ADC launch, Capstan CAR-T acquisition
- **Margin Strength**: 84.4% gross margin, 44.3% operating margin
- **Strategic Moves**: $10B U.S. manufacturing expansion, Gubra amylin partnership
- **Risks Mitigated**: Venclexta IRA exemption, diversified manufacturing
- **Key Drivers**: Immunology (+22%), Neuroscience (+24%), Oncology (+8%) growth

**【CEO Summary Section】**
- AbbVie reported Q2 2025 adjusted EPS of $2.97, $0.11 above guidance, with total net revenues of $15.4 billion, $400 million ahead of expectations.
- Ex-HUMIRA platform growth of 22% driven by Skyrizi ($4.4B, +61.8%) and Rinvoq ($2B, +41.2%), on track for combined $25B+ annual sales.
- Full year guidance raised: revenue to $60.5B (+$800M) and adjusted EPS to $11.88-$12.08 (+$0.21). 
- Pipeline progress includes Rinvoq GCA approval, EMRELIS ADC launch, and Capstan CAR-T acquisition.
- 2025 R&D investments support long-term growth in immunology, oncology, and neuroscience.

**【CFO Financial Commentary】**
- Q2 2025 financial highlights:
  - Adjusted gross margin: 84.4% of sales
  - R&D expense: 13.7% of sales
  - SG&A expense: 21% of sales
  - Operating margin: 44.3% of sales (5.3% IPR&D impact)
- 2025 guidance:
  - Skyrizi: $17.1B (+$600M)
  - Rinvoq: $8.0B
  - Neuroscience: $10.5B (+$300M)
  - Oncology: Imbruvica $2.9B, Venclexta $2.8B
- Q3 2025 outlook: $15.5B net revenues, $3.24-$3.28 EPS

**【Q&A Highlights】**
- **Biosimilar Impact**: Skyrizi/Rinvoq growth driven by clinical differentiation, not biosimilar displacement. Sequence head-to-head trial boosted IBD share gains.
- **Aesthetics Strategy**: TrenibotE short-acting toxin launch in 2026 to reinvigorate filler market; obesity drug pipeline expansion via Gubra amylin partnership.
- **Oncology Pipeline**: Temab-A ADC showing 63% ORR in NSCLC, PVEK for BPDCN on track for 2025 submission.
- **Neuroscience Momentum**: QULIPTA outperforms topiramate in TEMPLE trial, VYALEV Parkinson's launch exceeds expectations.
- **Tariff Preparedness**: 11 U.S. manufacturing sites, $10B+ capital investment to insulate from EU tariffs.
- **IRA Negotiations**: Venclexta exempt under expanded orphan drug rule; no impact on 2025 financials.

AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript

- **Q1 2025 Strong Performance**: Adjusted EPS of $2.46 (+$0.10 vs. midpoint), $13.3B net revenues, ex-Humira platform up 21%.
- **Pipeline Momentum**: Skyrizi/Rinvoq up 65%, Rinvoq GCA FDA approval pending; Amylin analog ABBV-295 shows 7.8% weight loss in Phase 1.
- **Strategic Investments**: $10B+ US manufacturing expansion; 2025 R&D spend $8.9B (15.4% of sales).
- **Tariff Risk Management**: Guidance excludes tariff impact; US manufacturing network (11 sites, 6,000+ employees) provides resilience.
- **Key Product Updates**: BoNT/E NDA filed; Teliso-V Q2 ADC approval; Tavapadon Phase 3 application planned.

**【CEO Summary Section】**
- AbbVie reported Q1 2025 adjusted EPS of $2.46, exceeding the guidance midpoint by $0.10, with total net revenues of $13.3 billion, $550 million above expectations.
- The ex-Humira platform grew 21%, driven by immunology (Skyrizi/Rinvoq combined sales up 65%), oncology (Imbruvica/Venclexta), and aesthetics.
- Full-year adjusted EPS guidance raised to $12.09-$12.29, reflecting confidence in the pipeline and US manufacturing investments ($10B+ over 10 years).
- Tariff risks noted, but guidance assumes no impact; US manufacturing presence (11 sites, 6,000+ employees) provides mitigation flexibility.

**【CFO Financial Commentary】**
- Q1 2025 GAAP net income: $420M; Non-GAAP EPS: $2.46 (vs. $2.36 prior guidance midpoint).
- Gross margin: 84.1% of sales; R&D/S&A expenses: 15.4%/24.6% of sales; Operating margin: 42.3% (1.9% drag from acquired IPR&D).
- Full-year 2025 guidance: $59.7B net revenues (+$700M vs. prior); Skyrizi/Rinvoq up $600M/$300M; US Humira down $500M due to biosimilar erosion.
- 2025 R&D investment: $8.9B (15.4% of sales), supporting pipeline growth.

**【Q&A Highlights】**
- **Immunology Pipeline**: Skyrizi/Rinvoq Q1 2025 sales up 65%, with IBD share at 15% (Crohn's 1/2 in-play, UC 1/3 in-play). Rinvoq GCA FDA approval expected soon.
- **Tariff Mitigation**: US manufacturing expansion ($10B+ over 10 years) and cost efficiencies; 2025 guidance excludes tariff impact.
- **Obesity Program**: Amylin analog ABBV-295 Phase 1 data shows 7.8% weight loss vs. 2% placebo at 2mg; Phase 2b to test higher doses and 12-week dosing.
- **Aesthetics**: BoNT/E (fast-acting toxin) NDA filed; co-administration with BOTOX could expand market. China approvals for BOTOX masseter and VOLUX drive share recovery.
- **Oncology**: Teliso-V (c-Met ADC) Q2 accelerated approval; tmAb A Phase 1 data to be presented at ASCO.
- **Neuroscience**: Tavapadon Phase 3 application planned for late 2025; VYALEV (Parkinson's) US Medicare coverage expansion underway.


AbbVie (ABBV)-25 Apr 25-2025 Q1 Earnings call transcript

- **Record 2024 Performance**: $56.3B revenue, $10.12 EPS, ex-HUMIRA +18% growth.
- **Skyrizi/Rinvoq Supercharge**: 2025 sales $24B, 2027 target $31B (+$4B vs. prior guidance).
- **2025 Outlook**: $59B revenue, 5.7% growth. Free cash flow $17B, dividend growth.
- **Pipeline Momentum**: 20+ new deals, ADC assets (Teliso-V, Tmab-A), Tavapadon Parkinson's success.
- **Aesthetics Recovery**: 2025 sales $5.3B, 8% CAGR to 2029. Share rebound post-program reset.
- **Part D Impact**: 4% growth headwind in 2025, offset by immunology/oncology strength.


**【CEO Summary Section】**
- Full year 2024 adjusted EPS of $10.12, exceeding initial guidance by $0.49. Total net revenues of $56.3 billion, surpassing guidance by $2 billion.
- Ex-HUMIRA platform delivered 18% operational revenue growth, with Q4 growth accelerating to 22%. 2025 revenue guidance of $59 billion reflects 5.7% operational growth.
- Skyrizi and Rinvoq expected to generate $24 billion in 2025, up $6 billion year-over-year. 2027 combined sales target raised to $31 billion, $4 billion above prior guidance.
- Neuroscience and oncology growth driven by VYALEV, VENCLEXTA, and ELAHERE. Aesthetics long-term CAGR of 8% through 2029 despite near-term challenges.

**【CFO Financial Commentary】**
- Q4 2024 adjusted EPS of $2.16, $0.08 above midpoint of guidance. Total net revenues $15.1 billion, 6.1% operational growth.
- 2025 adjusted EPS guidance of $12.12-$12.32, excluding IPR&D expenses. Gross margin expected at 84%, R&D spend 14.5%, SG&A $13.2 billion.
- Free cash flow of $17 billion in 2025, supporting dividend growth and $3 billion debt repayment. Net leverage target of 2x by end-2026.

**【Commercial Highlights】**
- **Immunology**: Skyrizi/Q4 sales $3.8B (+58%), Rinvoq $1.8B (+47%). UC launch drives IBD share, Skyrizi/Rinvoq capture ~50% Crohn's in-play.
- **Oncology**: VENCLEXTA $655M (+13%), ELAHERE $148M (U.S. annualizing $600M). Teliso-V ADC targeting C-MET+ NSCLC with 2025 FDA decision.
- **Neuroscience**: VYALEV $924M, BOTOX Therapeutic $873M. Tavapadon Phase III success in Parkinson's, 2025 regulatory submissions.
- **Aesthetics**: Q4 U.S. sales $839M (-5%), share loss due to loyalty program complexity. 2025 recovery expected with re-launched original program.

**【Pipeline & R&D】**
- **Immunology**: Skyrizi head-to-head vs. Sotyktu (2025), Rinvoq new indications (GCA, vitiligo). Lutikizumab Phase II for atopic dermatitis.
- **Oncology**: Teliso-V ADC for NSCLC, Tmab-A for colorectal cancer. ABBV-706 for small cell lung cancer.
- **Neuroscience**: Emracaladine Phase II for schizophrenia, Tavapadon monotherapy Phase III.

**【Q&A Key Takeaways】**
- **Pricing Dynamics**: Skyrizi/Rinvoq see low single-digit price declines, offset by 20%+ volume growth. 2025 Part D redesign 4% headwind.
- **Aesthetics Recovery**: U.S. market share rebounding post-loyalty program reset. 2025 aesthetics sales $5.3B, 8% CAGR to 2029.
- **ADC Pipeline**: Teliso-V potential first C-MET ADC for NSCLC. Tmab-A Phase III in CRC with 2025 data.
- **M&A Strategy**: 20+ early-stage deals in 2024, focusing on immunology, oncology, neuroscience. Cerevel impairment reflects risk-adjusted pipeline value.


ABBV

ABBV fundamentals

Earnings Call

You can ask Aime